Our findings collectively suggest that PET imaging using 89Zr-lintuzumab could be a powerful pre-clinical drug development tool to evaluate binding properties of anti-CD33 monoclonal antibodies in preclinical cancer models. This evidence concerns the gene CD33 and cancer.